2cureX is accelerating the launch of IndiTreat®
Press releases regulatory
2cureX AB (“2cureX”) hereby announces that the clinical validation of IndiTreat® is running according to plan and that the company has identified a strategic possibility to accelerate the development of IndiTreat® and to prepare a pre-launch of the product on selected markets already during the second half of 2019 followed by a potential earlier than expected market launch. The pre-launch and a potential earlier than expected market launch will not only enhance the possibility of successful treatment of cancer patients but also enable to generate earlier cash flow for 2cureX. A pre-launch and a potential earlier market launch will not require additional capital than what has been communicated earlier. The capital need will most likely arise during the first half of 2019 in order to successfully introduce the pre-launch and the following market launch of IndiTreat®.
2cureX is currently operating three clinical validation studies with IndiTreat® in colorectal, ovarian and pancreatic cancer together with clinical partners. The product has received CE-IVD marking, which means that 2cureX is entitled to sell IndiTreat® tests on the EES market. The fact that the IndiTreat® test is currently being clinically validated in three cancer indications has attracted great interest from oncologists and hospitals. 2cureX has therefore identified a strategic possibility to initiate a pre-launch of IndiTreat® in selected markets already in the second half of 2019. The clinical validation studies will be ongoing along with the market pre-launch, but the company assesses that early clinical data from the ongoing studies will be enough to initiate the market pre-launch followed by a potential earlier than expected market launch.
The pre-launch and a potential earlier market launch will not only enhance the possibility of successful treatment of cancer patients but also enable to generate earlier cash flow for 2cureX. 2cureX assesses that the capital need will arise during the first half of 2019 in order to successfully pre-launch IndiTreat® during the second half of 2019. As stated in the memorandum released prior to the IPO in October 2017, 2cureX has a capital need of approximately SEK 20 million to successfully launch IndiTreat®. The accelerated market launch will not require additional capital and it will not affect the objectives communicated in connection with 2cureX’s IPO in October 2017.
For more information about 2cureX:
|Ole Thastrup, Chief Executive Officer||Maarten van der Linden, Chief Business Officer|
|E-mail: email@example.com||E-mail: firstname.lastname@example.org|
|Telephone: +45 22115399||Telephone: +45 22902469|
Telephone: +46 40 615 14 15
This information is information that 2cureX AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on December 10th, 2018.
2cureX has developed a test called IndiTreat® (Individual Treatment Design), which is a patented and CE-IVD marked test for selecting the right drug for the right patient. IndiTreat® establishes thousands of 3D micro-tumors that are functionally similar to the patient’s tumor. From a large panel of approved cancer treatments IndiTreat® presents the best treatment for the individual patient. IndiTreat® is expected to become a standard tool in the treatment design for cancer patients.
IndiTreat® is currently being clinically validated in colorectal, ovarian and pancreatic cancer.
The company is listed at the Nasdaq First North stock exchange